The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.f

Hemolytic and uremic syndrome (HUS). See also under Xaf

Publications

Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.

Cancer. 1999;85(9):2023-32

Zimmerman SE, Smith FP, Phillips TM, Coffey RJ, Schein PS

Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations.

British medical journal (Clinical research ed.). 1982;284(6327):1432-4

Cantrell JE Jr, Phillips TM, Schein PS

Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985;3(5):723-34

Verweij J, van der Burg ME, Pinedo HM

Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1987;8(1):33-41

Sheldon R, Slaughter D

A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.

Cancer. 1986;58(7):1428-36